Company / EPS (Basic)
UroGen Pharma Ltd. EPS (Basic) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$2.96
FY2025
5-year range
-$4.96 / -$2.33
FY2022-FY2025
Trend
-27.0%
vs FY2024
Sector context
#151 of 208
Health Care
What the data says
At $-2.96, UroGen Pharma Ltd.'s eps (basic) ranks #151 of 208 in the Health Care sector. Improved from $-4.81 to $-2.96 over the past 2 years.
Based on SEC 10-K filings.
-2.96 in FY2025.
Improved from $-4.81 to $-2.96 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#151 of 208 in Health CareTop 73% of 208This company -$2.96 Sector average -$0.87
▼
-240.0% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) decreased 27.0% year-over-year.
- Ranks #151 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.96 | -27.0% |
| FY2024 | -$2.33 | +51.6% |
| FY2023 | -$4.81 | +3.0% |
| FY2022 | -$4.96 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026